The Precedent

The Precedent reports on corporate governance, institutional behaviour, accountability, and how companies and regulators maintain public trust.

[The Precedent @theprecedentX]

SGD Pharma showcased recycled-content glass at LuxePack NY, including bottles it says cut CO2 by up to 20% and a refillable jar that "encourages reuse."

The governance point is the gap inside one announcement. The PCR glass carries ISO 14021 certification, an external check. The CO2 figure and the reuse claim are company stated.

In sustainability messaging, "certified" and "claimed" are not the same word, and the difference is the whole credibility question.

[The Precedent @theprecedentX]

$UPM has launched purpose built adhesives for pharma, wine, and industrial labels, framing the choice around the "consequences when a label fails."

The governance point isn't the product. On a medicine vial, a label that lifts means a lost batch number or unreadable dose, a traceability gap nobody sees until it matters.

The claim to watch is "pre-assessed performance data."

Pre-assessed by whom, against what standard, is the difference between a compliance aid and a marketing phrase.

[The Precedent @theprecedentX]

At its core is a question of whether known health risks were adequately disclosed by a major global pharmaceuticals company.

$PFE response will be a bellwether for transparency and accountability across the pharma industry.

[The Precedent @theprecedentX]

Thousands of women are suing Pfizer, $PFE, over Depo-Provera, alleging the contraceptive injection raised their risk of brain tumours and that the risk wasn't adequately disclosed.

The governance question isn't the science alone. It's what a company knew, when, and whether warning fell behind the evidence.

Pfizer denies the claims and is contesting them.

[The Precedent @theprecedentX]

This builds on the US multidistrict litigation, which has grown from hundreds to over 3,000 claims. A 2024 BMJ study found long-term users faced a markedly higher meningioma risk, and in late 2025 the FDA required a label update.

The litigation has grown from 78 cases in March 2025 to over 3,700 as of June 2026.

[The Precedent @theprecedentX]

In late March, a pregnant woman in Gila County, Arizona was diagnosed with syphilis. One injection of penicillin could have protected her baby from this debilitating disease. Pfizer, $PFE, is the only company that makes it, and there has been a national shortage of the medication since 2025.

Officials filed an emergency request on March 27. Pfizer confirmed receipt, then the drug never came.

Months earlier, health directors had asked Pfizer to release a fraction of its reserves as a backstop. Pfizer said it was still evaluating the idea. A baby was born with a preventable disease while a company deliberated over paperwork.

https://t.co/GMHJSn3ZP3

[The Precedent @theprecedentX]

Biomunex has announced two AI collaborations to accelerate its cancer immunotherapy pipeline, and plans to extend AI into finance, HR, recruitment, and legal too.

The governance question isn't "should pharma use AI?" It's whether the oversight expands at the same pace as the deployment.

Adoption is announced. Controls rarely are.

[The Precedent @theprecedentX]

Samsung Bioepis has launched Opuviz, its Eylea biosimilar, across Europe, a cheaper alternative for serious eye conditions.

The governance story isn't the launch. It's that this drug was approved in late 2024 and only reaches patients now, after a patent settlement.

Regulatory approval and market access are two different gates. Litigation held the second shut.

[The Precedent @theprecedentX]

Kardigan has filed to list on the Nasdaq as KARD, with three cardiovascular drugs in late-stage trials and no approved product yet.

The governance question isn't "is the science good?" It's whether the prospectus disciplines expectations or rides the IPO wave's appetite for them.

A filing is where optimism becomes legally accountable.

[The Precedent @theprecedentX]

$CVS is suing Tennessee over a law barring PBMs from owning pharmacies, warning it would have to close 136 locations.

The governance question isn't "should CVS protect its business?" It's whether one company should set pharmacy reimbursement and own the pharmacies competing for it.

That dual role is the conflict the law targets.

[The Precedent @theprecedentX]

$AGIO is scrapping tebapivat in lower-risk MDS after a Phase IIb study missed its endpoint, while pointing to sickle-cell disease as the drug's future.

The governance question isn't "did the trial fail?" It's whether the failure is disclosed as plainly as the pivot is promoted.

How a company reports a miss is a credibility test.

[The Precedent @theprecedentX]

Newel Health and Gerresheimer AG $GX.DE have allied to help pharma embed AI, digital endpoints, and real-world data into trials and commercialisation.

The governance question isn't "is digital the future?" It's who is accountable for the validity of an endpoint when the drugmaker, the platform, and the device maker are three separate parties.

Shared infrastructure can mean diffused responsibility.

[The Precedent @theprecedentX]

The Chicago Plumbers' Welfare Fund's lawsuit against healthcare giant The Cigna Group $CI is a significant development in the growing scrutiny over the opaque network of organisations patients must navigate to access life-saving drugs.

The complaint implicates several major pharmaceutical companies, including Pfizer $PFE, Eli Lilly $LLY and Johnson & Johnson $JNJ. Pfizer is specifically accused of making payments to Ascent Health Services, a Group Purchasing Organisation, in exchange for favourable placement of its brand-name drugs in patient formularies.

@hntrbrkmedia's recent investigation found GPOs to be functioning as phantom middlemen, allowing major healthcare companies to avoid scrutiny over the growing drug rebates scandal.

[The Precedent @theprecedentX]

$MRK has won FDA Breakthrough Therapy designation for calderasib, its KRAS G12C inhibitor, on Phase 1 data.

The governance question isn't "is this promising?" It's whether the language around a designation keeps the gap between "expedited review" and "approved" visible to the public reading it.

A designation accelerates scrutiny. It doesn't replace it.

[The Precedent @theprecedentX]

Crescent Pharma has issued its third blood pressure medication recall, each one a packaging error at the same site.

The governance question isn't "do recalls happen?" It's whether a manufacturer that repeats the same failure can credibly claim its controls work.

A pattern is not an accident. It's evidence about the system that produced it.

[The Precedent @theprecedentX]

The FDA’s decision to publicly release Complete Response Letters changed how biotech and pharmaceutical companies communicated regulatory setbacks after years of companies controlling how rejection decisions were described to investors and the public.

The agency began publishing hundreds of FDA rejection letters tied to drug approval applications, giving analysts and investors direct visibility into issues related to safety, manufacturing, clinical data, and compliance concerns.

The policy increased pressure on companies to provide more accurate and transparent disclosures around regulatory decisions and corporate accountability.

[The Precedent @theprecedentX]

A German court has ordered Pfizer to stop using "near-complete stabilization" to describe tafamidis, finding the claim unsupported by its own data and label. Pfizer's US prescribing site continues to use the same phrase.

A court has now adjudicated the framing, not just the competitor. The case moved beyond a dispute between pharmaceutical competitors and into a broader question of corporate credibility.

Once a court rules that a scientific claim lacks evidentiary support, continued use of that language becomes a governance and communication issue as much as a legal one.

[The Precedent @theprecedentX]

San Francisco voters will decide on 2 June whether to expand the city's Overpaid Executive Tax, raising rates and adding a voter-approval requirement for future changes. The measure targets companies whose top-paid manager earns more than 100x the median worker.

Pay-ratio regulation by ballot is a different governance instrument from pay-ratio regulation by code. It moves the question of what executive compensation is for out of the boardroom and into the electorate. Whether the rate is right is one debate. Where the decision sits is the structural one.

[The Precedent @theprecedentX]

An audit at University Hospitals of Liverpool Group has found 48 staff accessed the medical records of Southport attack survivors without good reason.

This follows a near-identical breach at Nottingham University Hospitals involving Valdo Calocane victims.

Two NHS trusts. Two high-profile tragedies. The same failure of access control around the patients most exposed to public attention.

When the pattern repeats across institutions, the issue is no longer one trust's procedures. It is what the system regards as the baseline standard for patient dignity at its most vulnerable.